Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2019 1
2020 3
2021 5
2022 4
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
miR-21 in Human Cardiomyopathies.
Surina S, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M. Surina S, et al. Among authors: fontanella ra. Front Cardiovasc Med. 2021 Oct 27;8:767064. doi: 10.3389/fcvm.2021.767064. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34778418 Free PMC article. Review.
Tirzepatide prevents neurodegeneration through multiple molecular pathways.
Fontanella RA, Ghosh P, Pesapane A, Taktaz F, Puocci A, Franzese M, Feliciano MF, Tortorella G, Scisciola L, Sommella E, Ambrosino C, Paolisso G, Barbieri M. Fontanella RA, et al. J Transl Med. 2024 Jan 29;22(1):114. doi: 10.1186/s12967-024-04927-z. J Transl Med. 2024. PMID: 38287296 Free PMC article.
Corrigendum: miR-21 in Human Cardiomyopathies.
Surina, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M. Surina, et al. Among authors: fontanella ra. Front Cardiovasc Med. 2022 Apr 25;9:913429. doi: 10.3389/fcvm.2022.913429. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35548429 Free PMC article.
Evidence that tirzepatide protects against diabetes-related cardiac damages.
Taktaz F, Scisciola L, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Tortorella G, Puocci A, Sommella E, Signoriello G, Olivieri F, Barbieri M, Paolisso G. Taktaz F, et al. Among authors: fontanella ra. Cardiovasc Diabetol. 2024 Mar 30;23(1):112. doi: 10.1186/s12933-024-02203-4. Cardiovasc Diabetol. 2024. PMID: 38555463 Free PMC article.
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors.
Scisciola L, Taktaz F, Fontanella RA, Pesapane A, Surina, Cataldo V, Ghosh P, Franzese M, Puocci A, Paolisso P, Rafaniello C, Marfella R, Rizzo MR, Barbato E, Vanderheyden M, Barbieri M. Scisciola L, et al. Among authors: fontanella ra. Cardiovasc Diabetol. 2023 Feb 2;22(1):24. doi: 10.1186/s12933-023-01754-2. Cardiovasc Diabetol. 2023. PMID: 36732760 Free PMC article.
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials.
Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Puocci A, De Angelis A, Sportiello L, Marfella R, Barbieri M. Scisciola L, et al. Among authors: fontanella ra. Front Cardiovasc Med. 2022 Sep 6;9:1008922. doi: 10.3389/fcvm.2022.1008922. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36148061 Free PMC article. Review.
Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study.
Scisciola L, Paolisso P, Belmonte M, Gallinoro E, Delrue L, Taktaz F, Fontanella RA, Degrieck I, Pesapane A, Casselman F, Puocci A, Franzese M, Van Praet F, Torella M, Marfella R, De Feo M, Bartunek J, Paolisso G, Barbato E, Barbieri M, Vanderheyden M. Scisciola L, et al. Among authors: fontanella ra. Eur J Heart Fail. 2024 Feb;26(2):471-482. doi: 10.1002/ejhf.3145. Epub 2024 Jan 21. Eur J Heart Fail. 2024. PMID: 38247224
20 results